Neldivex (Nebivolol)

Nebivolol, the active ingredient in Neldivex, is a beta blocker presented as a tablet for oral use. It selectively lowers elevated blood pressure in adult patients with primary hypertension and is approved for long‑term management of this condition.\n\nGNH India supplies Neldivex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑conformant quality for global markets.

Nebivolol is a β1‑selective blocker used in the management of hypertension.\n\nHypertension: reduces systolic and diastolic blood pressure in adults with primary (essential) hypertension.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible.\n\nCommon Side Effects:\n- Headache: mild to moderate intensity, often transient.\n- Dizziness or light‑headedness: especially on standing.\n- Fatigue or tiredness: generally improves with continued therapy.\n- Nasal congestion: occasional mild stuffiness.\n- Gastrointestinal discomfort: mild nausea or abdominal pain.\n\nSerious or Rare Side Effects:\n- Bradycardia: heart rate markedly below normal, requiring medical assessment.\n- Severe hypotension: sudden drop in blood pressure with risk of syncope.\n- Acute heart failure exacerbation: worsening symptoms in susceptible patients.\n- Bronchospasm: especially in patients with underlying asthma or COPD.\n- Allergic reactions: rash, pruritus, or angioedema.

Nebivolol should be used with caution in specific clinical situations and patient populations.\n\nContraindicated in patients with severe bradycardia: avoid use if resting heart rate is <50 bpm.\nCaution in asthma or chronic obstructive pulmonary disease: monitor for bronchospasm.\nUse carefully in hepatic impairment: dose adjustment may be required.\nAvoid abrupt discontinuation: taper gradually to prevent rebound hypertension.\nMonitor blood pressure and heart rate regularly during therapy.\nStore at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Combined use with other β‑blockers: risk of excessive β‑blockade and severe bradycardia.\n- Concomitant strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase nebivolol plasma levels.\n- Severe hypotensive agents (e.g., potent vasodilators): can cause marked blood‑pressure fall.\n\nModerate Interactions (Monitor Closely):\n- Other antihypertensives (ACE inhibitors, ARBs, diuretics): may require dose adjustment.\n- Calcium‑channel blockers (especially verapamil, diltiazem): can enhance bradycardic effect.\n- Antidiabetic medications: nebivolol may mask hypoglycaemia symptoms; monitor glucose closely.